Table 2.

Changes in unesterified precursor fatty acids and oxylipins between weeks 14 and 24 in pregnancy without DHA supplementation (n = 21)

	Week 14	Week 24	p-value*
	Median (IQR)	Median (IQR)
Omega-6 fatty acids and oxylipins
LA**	7.6 (4.8, 11)	7.3 (4.1, 9.9)	.24
9-HODE	4.2 (1.4, 11)	3.4 (1.3, 7.9)	.42
13-HODE	11 (3.4, 23)	7.6 (5, 21)	.54
9,10-DiHOME	2.4 (1.1, 5.1)	1.6 (1.1, 4.3)	.56
13H-9,10E-LA	.25 (.16, .48)	.22 (.16, .36)	.73
9H-12,13E-LA	.16 (.067, .38)	.16 (.12, .24)	.93
9,12,13-TriHOME	.12 (.088, .19)	.14 (.098, .17)	.95
GLA	.086 (.044, .13)	.049 (.036, .074)	.030
DGLA	.12 (.086, .15)	.094 (.077, .11)	.059
AA	.18 (.14, .25)	.14 (.12, .17)	.011
5-HETE	.17 (.14, .23)	.16 (.12, .17)	.08
12-HETE	.13 (.1, .24)	.088 (.08, .12)	.039
15-HETE	.29 (.26, .5)	.21 (.17, .22)	.001
TxB2	.11 (.066, .22)	.053 (.039, .11)	.048
DTA	.045 (.034, .067)	.035 (.028, .048)	.033
DPA n-6	.042 (.033, .067)	.044 (.036, .05)	.45
Omega-3 fatty acids and oxylipins
ALA	.44 (.23, .79)	.26 (.18, .51)	.08
SDA (18:4 n-3)	.012 (.0061, .016)	.0058 (.0045, .0093)	.11
ETA (20:4 n-3)	.014 (.011, .018)	.012 (.0089, .014)	.15
EPA	.093 (.086, .1)	.083 (.056, .099)	.12
DPA n-3	.024 (.015, .038)	.023 (.016, .032)	.91
DHA	.65 (.43, .75)	.54 (.4, .78)	.97
4-HDHA	.066 (.042, .09)	.05 (.03, .076)	.57
10-HDHA	.026 (.021, .035)	.019 (.014, .038)	.11
14-HDHA	.12 (.085, .22)	.078 (.059, .12)	.06
17-HDHA	.17 (.13, .23)	.12 (.1, .19)	.55
19,20-EpDPA	.032 (.018, .047)	.034 (.019, .063)	.31
Other
Mead	.016 (.011, .02)	.011 (.0073, .013)	.003

^*Based on the Wilcoxon matched-pairs signed-ranks test.

^**9,10-EpOME & 9,10,13-TriHOME had >50% values below LOQ. Concentrations: fatty acids (ug/mL); oxylipins (ng/mL).